Skip to main content

Africa

South Africa and Sub-Saharan Africa

Asia Pacific

Europe

Belgium FR | NL

Bosnia & Herzegovina

Switzerland DE | FR

Latin America / Caribbean

Middle East

North America

Canada EN | FR

South America

Investors
News Center
Patient Assistance

Menu

Our Company
- Equity, Equality, Diversity & Inclusion
- Ethics & Compliance
- Policies & Disclosures
Our Science
- Therapeutic Focus Areas
- Pipeline
- Clinical Trials
Societal Impact
- For the Well-Being of Our Patients
- For the Growth of Our Employees
- For the Strength of Our Communities
- 对彩35app的业务的弹性
Careers
- Employee Resource Groups
- Roles
Partnerships
- AbbVie Ventures
- Additional Collaboration Opportunities

Investors
News Center
Patient Assistance

Type in your search...

Algeria

AbbVie Biopharmaceuticals GmbH

Hai Bouteldja Houidef,
Villa n° 12 rocade sud,
Ben Aknoun , Alger, Algérie

Stories
Patients
Suppliers
Contact

Follow us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Follow us on Instagram
Follow us on YouTube

Medical Information
Site Map
Privacy Policy
Terms of Use

Copyright © 2022 AbbVie Inc. North Chicago, Illinois, U.S.A.

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

You are about to leave the AbbVie website

The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?

Yes

I agree

No

You are about to leave for a 3rd party website

The link below will take you out of the AbbVie family of websites. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. The Internet site that you have requested may not be optimized to your screen size. Do you wish to leave this site?

Yes

Accept

No

Attention

The online application portal is for HUMIRA, RINVOQ, or SKYRIZI only. For all other medicines, please visit the Find My Medicine page.

Continue

Disclaimer Notice - Important

Recommended Offer for Allergan plc (“Allergan”) by AbbVie Inc. (“AbbVie”) (the “Acquisition”) by means of a scheme of arrangement under Irish law (the “Scheme”). You are attempting to enter the section of this website that is designated for the publication of documents and information in connection with the offer by AbbVie for Allergan announced on June 25, 2019 (the “Offer”). ACCESS TO THIS SECTION OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION. THE INFORMATION IS NOT DIRECTED AT, AND IS NOT INTENDED TO BE ACCESSIBLE BY, PERSONS RESIDENT IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. IF YOU ARE NOT PERMITTED TO VIEW THE INFORMATION, OR VIEWING THE INFORMATION WOULD RESULT IN A BREACH OF THE ABOVE, OR YOU ARE IN ANY DOUBT AS TO WHETHER YOU ARE PERMITTED TO VIEW THE INFORMATION, PLEASE EXIT THIS WEBPAGE. THIS SECTION OF THE WEBSITE CONTAINS ANNOUNCEMENTS, DOCUMENTS AND INFORMATION (TOGETHER THE "INFORMATION") RELATING TO THE OFFER IN COMPLIANCE WITH THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES 2013 (THE "IRISH TAKEOVER RULES"). THE INFORMATION IS BEING MADE AVAILABLE IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY, AND ITS AVAILABILITY IS SUBJECT TO THE TERMS AND CONDITIONS SET OUT BELOW. THE INFORMATION IS NOT INTENDED TO, AND DOES NOT, CONSTITUTE OR FORM ANY PART OF AN OFFER TO SELL OR OTHERWISE DISPOSE OF OR AN INVITATION OR THE SOLICITATION OF AN OFFER TO PURCHASE OR OTHERWISE ACQUIRE ANY SECURITIES, OR THE SOLICITATION OF A VOTE OR APPROVAL PURSUANT TO THE INFORMATION OR OTHERWISE. ANY PERSON SEEKING ACCESS TO THIS SECTION OF ABBVIE’S WEBSITE REPRESENTS AND WARRANTS TO ABBVIE THAT THEY ARE DOING SO FOR INFORMATION PURPOSES ONLY. BASIS OF ACCESS TO INFORMATION Please read this notice carefully before clicking "I agree" or "I disagree" below. This notice applies to all persons who view this section of the website and, depending on where you live, it may affect your rights. This notice may be amended or updated by AbbVie from time to time and it should be read carefully in full each time you wish to view the website. In addition, the content of the website, and its accessibility by certain persons, may be amended at any time in whole or in part at the sole discretion of AbbVie. The Information speaks only at the date of the relevant document or announcement and AbbVie has, and accepts, no responsibility or duty to update any Information (other than to the extent such duty arises as a matter of law or regulation).

Accept and continue

I agree

Return to AbbVie.com Home

I disagree